Regentis Biomaterials Ltd. (NYSE American: RGNT) is making strides toward commercializing its GelrinC® hydrogel implant, a cell-free, off-the-shelf solution for knee cartilage repair. The company announced that it is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved regenerative solution currently exists. GelrinC® is designed to simplify the repair process through a single-step, approximately 10-minute procedure, offering an alternative to traditional microfracture and complex cell-based therapies.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The implant is already CE Mark approved in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
The company’s Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate the cartilage in a controlled and synchronous process. This approach aims to address a significant unmet need, as no off-the-shelf treatment is currently available for the approximately 470,000 annual knee cartilage repair cases in the U.S.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, the company’s lead product GelrinC® represents a potential breakthrough in cartilage repair. For a full corporate profile, visit https://ibn.fm/bpPp6.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings. Undue reliance should not be placed on these statements, and the company undertakes no duty to update them unless required by law. For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones.